Aminophylline Injection, Solution
Product Images NDC 0404-9814

Table 1 displays the mean and range of total body clearance and half-life of theophylline related to age and altered physiological states. The data includes various populations such as postnatal infants, children, and adults with altered health conditions and functioning. It also includes demographics such as non-smoking asthmatics and non-smokers with normal cardiac, liver, and renal function.*

This is a table with recommended initial theophylline infusion rates based on patient population and age. Infusion rates are measured in mg/kg/hr, and the rates vary depending on the patient’s age and health status, including whether the patient is a smoker or non-smoker. The table also includes guidelines for achieving target concentrations of theophylline for certain medical conditions and warns against exceeding certain dosage levels unless indicated by serum levels. Ideal body weight is recommended for obese patients. If the text is not readable, please provide the image or document again.*

This is a dosage adjustment table for the use of theophylline based on a patient's serum concentration. The table provides guidance for dosage adjustments based on specific ranges of serum concentration. It suggests either increasing, maintaining or decreasing the infusion rate by a certain percentage, and rechecking serum concentration after 12 or 24 hours, depending on age. It also recommends considering adding additional medication(s) to the treatment regimen if symptoms are not controlled, and treating overdose if the serum concentration exceeds a certain value. The table indicates that dose reduction and/or serum concentration measurement is necessary whenever adverse effects are present, physiologic abnormalities occur, or a drug that interacts with theophylline is added or discontinued.*

This is a description of two different products, both of which come in a 25 in a carton. The first product has a total strength of 250 mg/10 mL, with a concentration of 25 mg/ml. The second product has a total strength of 500 mg/20 mL, also with a concentration of 25 mg/ml.*

This is a medical report that describes the rates of elimination and dosage requirements of theophylline among North American patient populations from various reports. The report also includes different medical conditions such as Acute pulmonary ecems, COPD with cor pumonle, cystic bross, liver disease, acute nepatitis, and cholestasis, among others, along with their associated values and ranges. The report mentions that the clearance rate and dosage requirements may vary based on the serum concentration of the drug.*

This is a table of clinically significant drug interactions with Theophylline. The table shows different drugs that interact with Theophylline and the effect of the interaction. The drugs include Adenosine, Alcohol, Allopurinol, Aminoglutethimide, Carbamazepine, Cimetidine, Ciprofloxacin, Cerithromycin, Diazepam, Distlfram, Enoxacin, and Ephedrine. The effects range from an increase in required dose to achieve the desired effect to a decrease in clearance, synergistic CNS effects, and increased frequency of nausea, nervousness, and insomnia.*

This text provides information on how different medications affect the clearance of theophylline, a drug commonly used to treat respiratory conditions. The text specifically mentions the effects of erythromycin, estrogen-containing oral contraceptives, flurazepam, fluvoxamine, halothane, human recombinant alpha-A interferon, soproterenol, ketamine, lithium, lorazepam, methotrexate, mexiletine, midazolam, and moricizine on the clearance of theophylline. The effects mentioned include increases or decreases in theophylline clearance, as well as changes in serum concentrations.*

This document contains information regarding drug interactions with theophylline, a medication used for respiratory problems. The text lists various drugs that can increase or decrease the clearance of theophylline and alter its effectiveness. The drugs mentioned include Pancuronium, Pentoxifylline, Phenobarbital (PB), Phenytoin, Propafenone, Propranolol, Rifampin, Sulfinpyrazone, Tacrine, Thizbendazole, Trolezndomycin, and Verapamil. These drugs can either increase or decrease theophylline clearance, which can impact the efficacy and may require larger doses to achieve neuromuscular blockade.*

The text provides cautionary information for drug interactions and recommends referring to additional sections for further details. It also mentions the average effects on steady-state theophylline concentration or other clinical effects for pharmacologic interactions, but notes that individual patients may experience larger changes in serum theophylline concentration than the listed average value.*

This is a table listing drugs that have been documented to have no interaction or produce no clinically significant interaction with theophylline. It includes drugs such as albuterol, amoxicillin, atenolol, and prednisone, among others. The table also advises referring to precautions and drug interactions for more information.*

This is a table presenting the percentage of patients who reported signs or symptoms of Theophylline Toxicity from two studies - one on acute overdose and the other on chronic over dosage. The table lists various symptoms and signs, such as vomiting, abdominal pain, diarrhea, hypokalemia, acid/base disturbance, and cardiovascular symptoms like sinus tachycardia, other supraventricular tachycardias, ventricular premature beats, and atrial fibrillation or flutter. Certain entries have "NR" as their value, which probably means "not reported."*

This text contains data related to the incidence of various symptoms and outcomes associated with the toxicity of the drug theophylline, including ventricular arrhythmias, hemodynamic instability, hypotension/shock, nervousness, tremors, disorientation, seizures, and death. The data was obtained from two studies, one prospective and one retrospective, both involving patients with serum theophylline concentrations greater than 30 mg/mL. However, some data was not reported in a comparable manner between the two studies.*